PMID- 38130300
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231223
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 12
IP  - 11
DP  - 2023 Nov 30
TI  - Fruquintinib in combination with sintilimab or TAS-102 as third-line or above 
      treatment in patients with metastatic colorectal cancer: a real-world study.
PG  - 3034-3044
LID - 10.21037/tcr-23-867 [doi]
AB  - BACKGROUND: For metastatic colorectal cancer (mCRC), the efficacy of third-line 
      or above treatments is not ideal. Combining targeted vascular endothelial growth 
      factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) biological 
      agents with chemotherapy or anti-programmed death receptor 1 (PD-1) treatment can 
      bring longer survival benefits to patients with mCRC compared with the 
      application of a single drug. In this study, fruquintinib was used as the 
      research drug, and the main purpose was to compare the efficacy and safety of 
      fruquintinib in combination with sintilimab (FS) or trifluridine and tipiracil 
      (TAS-102) (FT) in the third-line or above treatment in mCRC patients. METHODS: 
      Based on real-world clinical practice, mCRC patients who progressed after 
      second-line or higher-line chemotherapy regimens and received FS or FT as 
      third-line or above treatment from December 2020 to November 2022 were analyzed. 
      Progression-free survival (PFS) was the primary endpoint. Safety, disease control 
      rate (DCR) and objective response rate (ORR) were secondary end points. RESULTS: 
      In the FS group, 47 patients received FS, and in the FT group, 45 patients 
      received FT. The DCR values in the FS and FT groups were 80.9% (38/47) and 55.6% 
      (25/45), respectively (P<0.05). The median PFS (mPFS) in the FS group was 6.0 
      months, and the mPFS in the FT group was 3.5 months (P<0.05). Most adverse events 
      (AEs) were grade 1-2 in severity. CONCLUSIONS: As a third-line or above regimen 
      in mCRC patients, compared to FT, treatment with FS provides a higher DCR and 
      longer mPFS and is better tolerated. The combination of fruquintinib and 
      sintilimab may become a new treatment option for mCRC patients.
CI  - 2023 Translational Cancer Research. All rights reserved.
FAU - Li, Luchun
AU  - Li L
AD  - Department of Oncology, Chongqing University, Cancer Hospital, Chongqing, China.
FAU - Wang, Ting
AU  - Wang T
AD  - Department of Oncology, Chongqing University, Cancer Hospital, Chongqing, China.
FAU - Wu, Zhijuan
AU  - Wu Z
AD  - Department of Oncology, Chongqing University, Cancer Hospital, Chongqing, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Oncology, Chongqing University, Cancer Hospital, Chongqing, China.
FAU - Ma, Huiwen
AU  - Ma H
AD  - Department of Oncology, Chongqing University, Cancer Hospital, Chongqing, China.
FAU - Wang, Lulu
AU  - Wang L
AD  - Department of Radiotherapy, Chongqing University, Cancer Hospital, Chongqing, 
      China.
FAU - Lei, Shuangyi
AU  - Lei S
AD  - Department of Oncology, Chongqing University, Cancer Hospital, Chongqing, China.
FAU - Chen, Wen
AU  - Chen W
AD  - Department of Oncology, Chongqing University, Cancer Hospital, Chongqing, China.
LA  - eng
PT  - Journal Article
DEP - 20231030
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC10731331
OTO - NOTNLM
OT  - Metastatic colorectal cancer (mCRC)
OT  - fruquintinib
OT  - progression-free survival (PFS)
OT  - sintilimab
OT  - trifluridine and tipiracil (TAS-102)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://tcr.amegroups.com/article/view/10.21037/tcr-23-867/coif). All authors 
      report receiving funding from the Chongqing Natural Science Foundation (No. 
      cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) 
      and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project. The 
      authors have no other conflicts of interest to declare.
EDAT- 2023/12/22 06:42
MHDA- 2023/12/22 06:43
PMCR- 2023/11/30
CRDT- 2023/12/22 03:45
PHST- 2023/05/28 00:00 [received]
PHST- 2023/09/28 00:00 [accepted]
PHST- 2023/12/22 06:43 [medline]
PHST- 2023/12/22 06:42 [pubmed]
PHST- 2023/12/22 03:45 [entrez]
PHST- 2023/11/30 00:00 [pmc-release]
AID - tcr-12-11-3034 [pii]
AID - 10.21037/tcr-23-867 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2023 Nov 30;12(11):3034-3044. doi: 10.21037/tcr-23-867. Epub 
      2023 Oct 30.